Puri, B K · Prostaglandins, leukotrienes, and essential fatty acids · 2004 · DOI
This study looked at whether a supplement containing high amounts of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid found in fish oil, could help people with ME/CFS. A small group of patients took this supplement and most reported feeling better within 8-12 weeks. The researchers suggest that EPA might be a helpful treatment option for some people with this condition.
This study opens a potentially accessible therapeutic avenue for ME/CFS patients, as EPA supplementation is relatively safe and available over-the-counter. It bridges basic science observations about fatty acid metabolism in ME/CFS with clinical outcomes, suggesting that metabolic interventions warrant further investigation. For patients seeking non-pharmaceutical options, the results provide preliminary hope.
This study does not prove that EPA is an effective treatment for ME/CFS, as it lacks a proper control group and used only case reports. The improvements observed could reflect placebo effect, natural disease fluctuation, or other concurrent factors rather than EPA's specific action. The small sample size and lack of blinding mean these findings require confirmation in rigorous, randomized controlled trials before clinical recommendations can be made.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.